Satellos Bioscience Inc.
MSCLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.23 | 2.94 | 0.12 |
| FCF Yield | -4.88% | -5.78% | -7.86% | -8.14% |
| EV / EBITDA | -10.96 | -7.18 | -9.42 | -6.28 |
| Quality | ||||
| ROIC | -17.60% | -16.70% | -15.71% | -11.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.86 | 1.20 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 14.80% | 34.21% | 5.66% | -78.39% |
| Safety | ||||
| Net Debt / EBITDA | 3.24 | 6.00 | 5.05 | 9.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -63,050.08 | -93,897.64 | -25.96 | 0.00 |